ProFrac Holding Corp. (ACDC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

ProFrac Holding Corp. (ACDC) reported Q2 2025 revenue of $501.9 million, a 13.4% year-over-year decline, which marginally exceeded analyst estimates by 0.52%. However, the company posted a significant earnings per share (EPS) miss, reporting -$0.67 compared to an estimated -$0.29 and $0.02 in the prior year, representing a -131.03% surprise. This substantial EPS miss, particularly alongside an Adjusted EBITDA miss in Stimulation Services, has contributed to ACDC shares declining 16.6% over the past month, contrasting sharply with the S&P 500's 1.2% gain, and results in a Zacks Rank #4 (Sell) indicating potential near-term underperformance.

Analysis

ProFrac Holding Corp. (ACDC) reported challenging second-quarter 2025 results, defined by a severe bottom-line miss despite marginally beating revenue expectations. The company's revenue of $501.9 million marked a 13.4% year-over-year decline but edged past the consensus estimate by 0.52%. More critically, the reported earnings per share (EPS) of -$0.67 represented a significant deterioration from the $0.02 earned in the year-ago quarter and constituted a -131.03% negative surprise relative to the -$0.29 Wall Street estimate. A deeper look at segment performance reveals significant weakness in the core Stimulation Services unit, where both revenue and Adjusted EBITDA ($51.1 million) fell short of analyst projections, with EBITDA missing by a substantial margin against a $72.66 million estimate. While the Manufacturing segment delivered a notable Adjusted EBITDA beat, this was insufficient to offset the core weakness and revenue misses in both Stimulation and Manufacturing. This fundamental underperformance has been reflected in the stock's recent price action, with shares falling 16.6% over the past month, starkly underperforming the S&P 500 composite's 1.2% gain and aligning with the current Zacks Rank #4 (Sell) designation.

Key Decisions for Investors

• Given the substantial EPS miss and significant underperformance in the core Stimulation Services' Adjusted EBITDA, investors should exercise caution, as the results signal deteriorating profitability and operational challenges.
• The stock's sharp -16.6% decline over the past month suggests the market is reacting negatively, and the Zacks Rank #4 (Sell) indicates a high probability of continued near-term underperformance.
• Investors should closely monitor future earnings reports for any signs of stabilization or recovery in the Stimulation Services segment, as its performance is a critical driver for the company's overall financial health.